Eight Mid-Caps With Net Cash, 23% ROIC, and Almost No Analyst Coverage

The S&P 500’s top ten companies now command 35% of total index weight. They trade at roughly 30x forward earnings. The other 490 trade at 20x. The cap-weighted index has become a directional bet on AI capex and a handful of hyperscaler balance sheets.

That bet may pay off. It may not. Either way, it is a single bet.

We went looking for the alternative — businesses that generate their own cash, hold it on the balance sheet, compound capital efficiently, and trade without a crowd of analysts pricing every quarter to perfection. We found eight.

What’s Wrong With the Index

The top-10 weight reached 41% of the S&P 500 in 2025, up from a 1990–2015 range of 18–23%. But those same ten names produce only ~32% of the index’s earnings. The mismatch closed faster in 2000–2003 than most investors expected.

The Magnificent Seven accounted for ~31% of total S&P 500 capex in 2025 — nearly double their 2023 share. Hyperscaler capex now equals 4–5% of total U.S. private domestic investment, a share that previously belonged to telecoms during 1999–2000. Whether this round of capex earns its cost of capital is the single biggest question hanging over the cap-weighted index.

The answer materially does not affect the basket below.

Mid-Caps at the Widest Discount in a Decade

Forward P/E spread between the S&P 500 and Russell Midcap has widened to roughly 5 multiple points (~22x vs ~17x). The 20-year median spread is ~2 points. Mid-caps trade at the deepest discount to large-caps in over a decade.

Drill one layer down and the gap is wider still. Russell Midcap Value trades at 17.5x. Russell Midcap Growth trades at 33x. That 15.7-point spread isn’t seen outside the dot-com era and the immediate COVID shock.

Mid-caps additionally offer 70–85% domestic revenue, structurally lower coverage (median 13 analysts vs. 27 for the S&P 500), and historical rolling 5- and 10-year outperformance versus both the Russell Top 200 and Russell 2000.

Starting valuation drives long-term returns more than any other variable. The basket’s median FCF yield is 4.9% versus 3–4% for the cap-weighted S&P 500.

The Screen

The screen is rules-based. Starting universe: Russell Midcap (~800 names, smallest 800 of the Russell 1000). Banks, insurers, broker-dealers, upstream E&P, pre-revenue biotech, and companies public less than 5 years are excluded before any quantitative filter runs.

The hard gates: market cap $2B–$20B; net cash, or net debt ≤1.5x EBITDA (tighter than the typical investment-grade threshold of ~3x); FCF margin ≥8%; positive FCF in four of the last five fiscal years; ROIC ≥10% and stable; buyback + dividend yield ≥2% on a 3-year average; revenue CAGR ≥3% over five years.

Then the narrative-poor filter: 12 or fewer sell-side analysts publishing estimates. This is the mispricing window.

800 names in. Eight out.

The Eight

Equal-weighted, the basket median delivers a 20% FCF margin and 23% ROIC — versus roughly 7% and 9% for the Russell Midcap median. Six of the eight have nine or fewer analysts publishing estimates.

• InterDigital (IDCC) — Wireless and video patent licensing. 38,000 patents, 71% adjusted EBITDA margin, $1.2B net cash on an $8B market cap. Samsung renewal signed 2025; HP licensed 2025; Disney injunctions secured.

• Mueller Industries (MLI) — North America’s leading copper, brass, and aluminum products manufacturer. $1.39B net cash, essentially zero debt, 5.9:1 current ratio. Quarterly dividend raised 40% in February 2026. Five sell-side analysts.

• Watts Water Technologies (WTS) — Water infrastructure (backflow preventers, water heaters, drainage). 105% cash conversion of net income to FCF. Acquired Haws Corporation in November 2025 — funded entirely from cash, exited the year still net cash.

• Carlisle Companies (CSL) — Pure-play building envelope (commercial roofing, weatherproofing) after the 2024 sale of Carlisle Interconnect. The only basket member with net debt — 1.4x EBITDA, comfortably within the 1–2x management band. Returned $1.3B in 2025 buybacks (~10% of market cap).

• Exponent (EXPO) — Science and engineering consulting; 950+ consultants across 90+ technical disciplines. Debt-free for over a decade. 25% FCF margin, 21% ROIC. Counter-cyclical revenue tied to litigation and regulatory matters.

• Lancaster Colony (LANC) — Specialty foods (Marzetti, Sister Schubert’s, New York Bakery). Debt-free. 62 consecutive years of dividend increases — one of fewer than 12 U.S. companies with that record.

• Medpace Holdings (MEDP) — Late-stage CRO serving small and mid-size biotech. 43% ROIC and 73% ROE — the highest in the basket. Debt-free since IPO. 6.8% of shares retired in FY2025 alone.

• Cohen & Steers (CNS) — Boutique asset manager focused on real assets and listed infrastructure. ~$80B AUM. 14-year dividend growth track record. Inflation-hedged income franchise positioned for a sticky-3% inflation regime.

Aggregate basket net cash: ~$1.6B against combined enterprise value of ~$70B.

How the Basket Behaves Across Scenarios

We sketched three regimes — bear, base, bull — assigned probability weights, and estimated cumulative basket return through December 2030 alongside the Russell Midcap and the S&P 500.

In a recession with sticky stagflation (probability 25%), we estimate the basket draws down ~12% versus –22% for the Russell Midcap and –30% for the S&P 500. Balance-sheet strength compresses but doesn’t eliminate the drawdown.

In the base case (slow growth, sticky 2.5–3% inflation, modest mid-cap re-rating, probability 50%), the basket compounds at +38% versus +28% for the Russell Midcap and +22% for the S&P 500.

In the bull case (soft landing, breadth recovery, mid-caps re-rate from 17x toward 21x, probability 25%), the basket returns +75% — modestly trailing the broad Russell Midcap’s +70% because lower-quality names re-rate more violently from cheaper starting valuations. That trade-off is the price of quality.

Probability-weighted: +34% basket vs. +27% Russell Midcap vs. +19% S&P 500.

The Drawdown Stress Test

Peer-equivalent stress testing — looking at how net-cash, low-leverage mid-caps with characteristics similar to the basket actually traded in 2008, 2020, and 2022 — suggests the basket would have drawn down roughly 30% less than the Russell Midcap median in each crisis.

Three-crisis average: basket –25% versus Russell Midcap –38% and S&P 500 –37%.

Balance-sheet quality compresses drawdowns. It doesn’t prevent them. But the difference between losing a quarter of your capital and losing more than a third is the difference between recovering in two years and recovering in five.

The Risks

Single-stock idiosyncratic risk. Twelve and a half percent per name; a 50% drawdown on any one holding is a 6.25% basket impact. The trade-off for a focused portfolio.

Cyclical exposure. MLI, CSL, and WTS carry direct U.S. construction exposure. MEDP carries biotech funding cycle exposure. CNS carries real-asset market exposure. In a synchronized recession, basket FCF would compress 15–25% from current levels.

Multiple compression on premium names. EXPO, LANC, and MEDP all trade at 30–36x P/E — 37.5% of the basket. In a sustained value rotation, these names face a real headwind independent of operating performance. The remaining five names trade at value-to-mid multiples and would benefit from the same rotation.

The Bottom Line

The cap-weighted index has become a single concentrated bet. The basket below it is selected on the opposite premise: balance sheets that fund themselves, FCF that doesn’t depend on capital markets, and businesses that compound through the cycle without needing a narrative tailwind. The probability-weighted return doesn’t beat the index in every regime — but it compresses the downside in the bear case to less than half what the S&P 500 carries, while retaining most of the upside. That asymmetry is the entire point.

Read the full report on the StockResearch platform

Disclaimer: This article is for informational purposes only and does not constitute financial or investment advice. Stock research analysts and affiliates may hold positions in the securities discussed. Mid-cap equities carry meaningful market, sector, liquidity, and idiosyncratic risk; Concentrated baskets are not appropriate for all investors and may underperform broadly diversified benchmarks for extended periods. Always conduct your own due diligence before making any investment decisions.